We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge.
- Authors
Scotto, Riccardo; Buonomo, Antonio Riccardo; Zumbo, Giulia; Di Fusco, Antonio; Esposito, Nunzia; Di Filippo, Isabella; Nobile, Mariano; Pinchera, Biagio; Schiano Moriello, Nicola; Villari, Riccardo; Gentile, Ivan
- Abstract
Despite the lightning-fast advances in the management of SARS-CoV after 2 years of pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration of monoclonal antibodies (mAbs) to reduce the risk of severe disease progression. We conducted a prospective study to evaluate the effectiveness of mAbs against SARS-CoV-2 among patients at risk for severe disease progression, namely elderly and those with comorbidities, before the omicron variant surge. Patients were treated with either casirivimab/imdevimab, sotrovimab, or bamlanivimab/etesevimab. The rates and risk factors for clinical worsening, hospitalization, ICU admission and death (unfavorable outcomes) were evaluated. A stratified analysis according to the presence of SARS-CoV-2 IgG was also performed. Among 185 included patients, we showed low rates of unfavorable outcomes (9.2%), which were more frequent in patients with chronic kidney disease (aOR: 10.44, 95% CI: 1.73–63.03; p < 0.05) and basal D-dimer serum concentrations > 600 ng/mL (aOR 21.74, 95% CI: 1.18–397.70; p < 0.05). Patients with negative SARS-CoV-2 serology at baseline showed higher C-reactive protein values compared with patients with positive serology (p < 0.05) and a trend toward a higher admission rate to SICU and ICU compared with patients with positive serology. Our results thus showed, in a real-life setting, the efficacy of mAbs against SARS-CoV-2 before an Omicron surge when the available mabs become not effective.
- Subjects
SARS-CoV-2 Omicron variant; MONOCLONAL antibodies; SARS-CoV-2; CHRONIC kidney failure; C-reactive protein
- Publication
Vaccines, 2022, Vol 10, Issue 11, p1895
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10111895